EASTONBIOPHARMACEUTICALS(SH:688513) Ge Long Hui·2025-09-23 10:10Group 1 - The core viewpoint of the articles is that the company, Yuandong Biotech, is actively pursuing strategic investments to enhance its capabilities in innovative drug development by increasing its stake in Shanghai Chaoyang [1][2] - The company plans to increase its strategic investment in Shanghai Chaoyang to achieve a controlling stake, which will enhance its research and development strength in the innovative drug sector [1] - The investment will allow the company to leverage Shanghai Chaoyang's differentiated targeted protein degradation technology platform and product pipeline, expanding its presence in critical therapeutic areas such as hematological malignancies and autoimmune diseases [1] Group 2 - The company has approved a capital increase of 85.71 million yuan for Shanghai Chaoyang, with the investment coming from its wholly-owned subsidiary, Shanghai Investment Company [2] - Following the capital increase, Shanghai Chaoyang's registered capital will rise from 88 million yuan to 125.71 million yuan, and the company's indirect ownership will increase from 30.68% to 51.48%, making Shanghai Chaoyang a controlled subsidiary [2] - The funding for this capital increase will be sourced entirely from the company's own funds, and the other shareholders of Shanghai Chaoyang have waived their preemptive rights for this round of investment [2]